Contrasting Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) & AdaptHealth (NASDAQ:AHCO)

AdaptHealth (NASDAQ:AHCO) and Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for AdaptHealth and Shandong Weigao Medical Polymer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AdaptHealth	0	2	5	0	2.71
Shandong Weigao Medical Polymer	0	0	0	0	0.00

AdaptHealth presently has a consensus price target of $13.60, suggesting a potential upside of 29.65%. Given AdaptHealth’s stronger consensus rating and higher possible upside, equities analysts plainly believe AdaptHealth is more favorable than Shandong Weigao Medical Polymer.

Volatility & Risk

AdaptHealth has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Shandong Weigao Medical Polymer has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of AdaptHealth shares are owned by institutional investors. 1.6% of AdaptHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares AdaptHealth and Shandong Weigao Medical Polymer”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AdaptHealth	$3.26 billion	0.44	$90.42 million	$0.55	19.07
Shandong Weigao Medical Polymer	$1.82 billion	1.70	$314.90 million	N/A	N/A

Shandong Weigao Medical Polymer has lower revenue, but higher earnings than AdaptHealth.

Profitability

This table compares AdaptHealth and Shandong Weigao Medical Polymer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AdaptHealth	2.53%	4.85%	1.75%
Shandong Weigao Medical Polymer	N/A	N/A	N/A

Summary

AdaptHealth beats Shandong Weigao Medical Polymer on 10 of the 12 factors compared between the two stocks.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.

About Shandong Weigao Medical Polymer

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers single use medical consumables and materials, including infusion sets, syringes, blood bags and blood component segregators consumable, blood sampling products, prefilled syringes for pre-pack medication and medical needles which mainly include intravenous needles, syringe needles, intravenous catheter needles, blood sampling needles and irregular needles; orthopedic materials and instruments, including trauma products of steel plates and screws, spinal implants, and artificial joints; and blood purification consumables and equipment, including puncture needles, extracorporeal blood circuit for blood purification sets, dialyzers and related consumables. It also provides tumour and blood vessel interventional instruments; flushing syringes; blood collection, irradiation, storage, separation and sterilization products; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; medical polymer materials and products; injection puncture Instruments; medicines; and X-ray based irradiation machines. In addition, it is involved in the finance leasing and factoring business; provision of enterprise management advisory services, logistics and storage, and computer technical services; and sale of electronic products. The company was incorporated in 2000 and is based in Weihai, the People’s Republic of China.